Nature biotechnology
-
Charitable foundations are increasingly looking to help promising drugs reach the market. Often the advice and networking opportunities they provide are as valuable as the funding.
-
Given that Californian voters authorized state coffers to sell $3 billion in bonds to fund the California Institute for Regenerative Medicine (CIRM) with the expectation of health and financial benefits, what benchmarks should be used to measure the initiative's success?
-
When US Food and Drug Administration (FDA) official Susan Wood resigned over foot-dragging on Plan B, she found herself at the center of a maelstrom concerning political interference in agency decision-making.
-
The thinking behind the US Food and Drug Administration's (FDA) draft guidance on financial conflicts of interest for outside experts is deeply flawed.